Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
7101-51-1
Molecular formula
C10H13NO4
Molecular weight
211.21 g/mol
Drug class
Levodopa prodrugmethyl ester of L-DOPA
Mechanism of action
Melevodopa is the methyl ester of levodopa. Following hydrolysis to levodopa, it enters the brain via amino-acid transport and is decarboxylated by aromatic L-amino-acid decarboxylase to dopamine, replenishing deficient striatal dopaminergic signalling.
Indications / reported uses
Investigated and used in some countries as a rapidly absorbed levodopa form for treatment of Parkinson’s disease, generally in combination with a peripheral dopa-decarboxylase inhibitor. Product availability and authorisation are jurisdiction-specific.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Melevodopa Environmental Risk Assessment (ERA) (the Melevodopa ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.